Advertisement
Singapore markets open in 6 hours 12 minutes

  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • Dow

    38,239.66
    +153.86 (+0.40%)
     

  • Nasdaq

    15,927.90
    +316.10 (+2.02%)
     

  • Bitcoin USD

    63,766.61
    +530.84 (+0.84%)
     

  • CMC Crypto 200

    1,394.98
    -1.56 (-0.11%)
     

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • Gold

    2,349.60
    +7.10 (+0.30%)
     

  • Crude Oil

    83.66
    +0.09 (+0.11%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • Nikkei

    37,934.76
    +306.26 (+0.81%)
     

  • Hang Seng

    17,651.15
    +366.65 (+2.12%)
     

  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     

  • Jakarta Composite Index

    7,036.08
    -119.21 (-1.67%)
     

  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

ARS Pharmaceuticals Inc (SPRY) Reports Full Year and Q4 2023 Financial Results

GuruFocus Research
·3-min read

  • Financial Position: Ended the year with $228.4 million in cash, cash equivalents, and short-term investments.

  • R&D Expenses: Research and development expenses increased to $20.3 million for the year, up from $18.4 million in 2022.

  • G&A Expenses: General and administrative expenses rose to $47.3 million for the year, a significant increase from $18.5 million in the previous year.

  • Net Loss: Reported a net loss of $54.4 million for the year, compared to a net loss of $34.7 million in 2022.

  • Regulatory Milestones: Preparing to submit response to the FDA's CRL for neffy in early Q2 2024, with a potential launch in the second half of the year.

  • Clinical Advancements: Positive clinical data from Phase 2 trial in chronic spontaneous urticaria, meeting primary endpoints.

ARS Pharmaceuticals Inc (NASDAQ:SPRY) released its 8-K filing on March 21, 2024, providing a business update and disclosing its financial results for the fourth quarter and full year of 2023. The company is at the forefront of developing neffy, a novel intranasal epinephrine product for the emergency treatment of Type I allergic reactions, including anaphylaxis.

Financial Highlights and Clinical Progress

ARS Pharmaceuticals Inc (NASDAQ:SPRY) concluded the fourth quarter with a robust financial position, boasting $228.4 million in cash, cash equivalents, and short-term investments. This capital is expected to support the company's operations for at least three years, including the anticipated second half of 2024 launch of neffy in the United States.

ADVERTISEMENT

Research and development expenses for the year amounted to $20.3 million, reflecting an increase from the previous year's $18.4 million. This rise is attributed to higher payroll costs and stock-based compensation, despite a decrease in license milestone expenses. General and administrative expenses also saw a substantial increase to $47.3 million for the year, up from $18.5 million in 2022, driven by pre-commercial launch activities and increased payroll and consulting costs.

The net loss for the year was reported at $54.4 million, compared to a net loss of $34.7 million in the previous year. This increase in net loss is consistent with the company's investment in research and development as well as pre-commercial and administrative activities.

Strategic Developments and Future Outlook

ARS Pharmaceuticals Inc (NASDAQ:SPRY) is preparing to respond to the FDA's Complete Response Letter (CRL) for neffy in early Q2 2024. The company has successfully completed necessary studies and assessments, including a repeat dose nasal allergen challenge study and nitrosamine testing, addressing the FDA's concerns. The expected review period could lead to an FDA action date and the potential launch of neffy in the latter half of 2024.

In addition to its regulatory efforts, ARS Pharmaceuticals Inc (NASDAQ:SPRY) has reported positive clinical data from a Phase 2 trial evaluating neffy in adults with chronic spontaneous urticaria, meeting all primary endpoints. This supports the advancement to an outpatient study, which is planned for later in 2024, potentially followed by a pivotal study in 2025.

ARS Pharmaceuticals Inc (NASDAQ:SPRY) is also making strides in intellectual property with the issuance of a new U.S. patent covering methods of treating Type I allergic reactions with intranasal epinephrine formulations. This patent further solidifies the company's innovative approach to allergy treatment.

The company's financial and clinical advancements in 2023 set the stage for a potentially transformative year ahead. With a strong cash position and promising clinical data, ARS Pharmaceuticals Inc (NASDAQ:SPRY) is well-positioned to continue its mission of providing a needle-free, safe, and effective epinephrine solution for patients at risk of severe allergic reactions.

For a detailed view of ARS Pharmaceuticals Inc (NASDAQ:SPRY)'s financials, please refer to the consolidated balance sheets and statements of operations included in the 8-K filing.

Explore the complete 8-K earnings release (here) from ARS Pharmaceuticals Inc for further details.

This article first appeared on GuruFocus.